July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Higher MAP targets in acute spinal cord injury show no neurologic benefit, more complications
- Sports medicine procedures cost far less in ASCs than HOPDs
- Bariatric surgery outpaces GLP-1s in weight loss, cost savings
- Study finds overweight older adults have lower postsurgical mortality than peers with normal BMI
- FDA posts four device safety communications, prompting inventory, workflow checks
- 7 strategies healthcare leaders can use to turn around toxic workplace culture
- Nutrition screening tool predicts poor outcomes after pancreatic cancer surgery
- CDC reports 460% surge in drug-resistant NDM-CRE infections
- 5 reasons why perioperative leaders deserve to attend the 2025 OR Manager Conference
- Global medical community rejects Trump’s Tylenol-autism claims: Statements compilation
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement